Buyout PE
SK Capital Partners
SK Capital Partners acquires controlling stakes in established, profitable businesses, from New York, New York. It states a focus on materials & chemicals and healthcare & life sciences.
Stated investment criteria
What SK Capital Partners says it buys
Read from SK Capital Partners’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.
A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. SK Capital Partners states that it takes majority or outright ownership. Nothing here is a commitment by SK Capital Partners to consider any particular business, and nothing on this page is represented as being for sale.
SEC filings
What SK Capital Partners has raised
From this firm's own Form D filings. A fund files one within fifteen days of its first sale, under penalty of perjury, which makes these the hardest numbers on the page.
| Vehicles filed | 8 |
| Total capital raised | $5.9bn |
| Largest single vehicle | $3.0bn |
| Filing history | 2014 to 2021 |
| Smallest accepted commitment | None stated |
| Filed from | NEW YORK |
Form D covers US-domiciled vehicles raised from accredited investors. It will not capture a fund raised outside the United States, separately managed accounts, or capital deployed off balance sheet, so treat these as a floor rather than a total.
Regulatory record
How SK Capital Partners is registered
From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.
| Adviser status | SEC registered |
| Regulatory assets under management | $8.4bn |
| Employees | 74 |
| Private funds advised | 28 · $8.8bn gross |
| SEC adviser number | CRD 161487 |
Portfolio
Disclosed holdings
Companies SK Capital Partners lists on its own website. 5 carry a stated investment year.
| Company | Invested | Years held | Recorded transaction |
|---|---|---|---|
| Canlak | 2021 | 5 | — |
| Deltech | 2021 | 5 | — |
| Apotex | 2023 | 3 | — |
| Axillon Aerospace | 2024 | 2 | — |
| Brothers International | 2026 | 0 | — |
| AEB Group | — | — | — |
| Archroma | — | — | — |
| Ecopol | — | — | — |
| Extractas | — | — | — |
| Florachem | — | — | — |
| Foremark Performance | — | — | — |
| Geon | — | — | — |
| Heubach | — | — | — |
| Ipackchem | — | — | — |
| Isolatek | — | — | — |
| J&K Ingredients | — | — | — |
| Lacerta | — | — | — |
| Luxium Solutions | — | — | — |
| Niacet | — | — | — |
| Noramco | — | — | — |
| Nucera Solutions | — | — | — |
| Perimeter Solutions | — | — | — |
| Polyventive | — | — | — |
| Precera Medical | — | — | — |
| SEQENS | — | — | — |
| Spectrum Vascular | — | — | — |
| Swixx BioPharma | — | — | — |
| Techmer PM | — | — | — |
| Tilley Distribution | — | — | — |
| Valtris | — | — | — |
| VanDeMark | — | — | — |
| Woodstock Sterile Solutions | — | — | — |
| ascendmaterials.com | — | — | — |
| halopharma.com | — | — | — |
| milestone-es.com | — | — | — |
| pptgroup.com | — | — | — |
| purisys.com | — | — | — |
| siigroup.com | — | — | — |
| spectraconfectionery.com | — | — | — |
| tpcgrp.com | — | — | — |
| venatorcorp.com | — | — | — |
| wavelengthpharma.com | — | — | — |
Compiled from SK Capital Partners’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.
Recorded transactions
Buying and selling
Deals in which SK Capital Partners is named as buyer or seller in the transaction archive. 3 recorded exits, most recently in 2023. 2 recorded acquisitions.
| Company | Side | Counterparty | Year | Consideration |
|---|---|---|---|---|
| Ipackchem | Sold | Greif | 2023 | $538m |
| NuCera Solutions | Sold | Chase | 2022 | $250m |
| Clariant Pigments | Bought | Clariant AG | 2021 | $836m |
| GEON | Bought | Avient | 2019 | $775m |
| Cambrex Drug Product- Business Unit | Sold | Cambrex | 2018 | $425m |
Compiled from a transaction archive of 10,204 recorded deals. Most private transactions are never disclosed, so this is a sample of a firm’s activity rather than a complete record of it.
Valuation context
Transaction values in Materials & Chemicals
What companies have actually sold for in materials & chemicals, across 401 recorded transactions.
The full materials & chemicals picture - most active acquirers, recent transactions and every investor in the sector.
For owners
Own a materials & chemicals business?
The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.
Request a confidential valuationFor investors
Is this SK Capital Partners?
Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.
Claim or correct this profileTargeted buyer search
Which hundred of these would actually buy your business?
A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.
Comparable investors
Similar mandates
Other buyout pe investors active in materials & chemicals.